الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 140 |  |  |
| | | from | 140 | | |
Abstract
RA is a common, chronic, autoimmune and disabling disease that largely affects the patient’s quality of life. Therefore, early diagnosis and effective treatment is required to control the disease progression and prevent joint damage. MTX is the most commonly used DMARD in RA treatment. However, MTX response varies widely among patients. A considerable percentage of patients show poor response to MTX. Therefore, prediction of MTX response can help to individualize MTX therapy and thus improve therapeutic outcome in RA patients.
RFC-1 G80A SNP is thought to be associated with MTX response in RA, but the results of the previous studies are conflicting. No previous studies have investigated the association between RFC-1 G80A SNP and MTX response among Egyptian RA patients.
The present study aimed to assess the association between RFC-1 G80A SNP (rs1051266) and MTX response in 74 Egyptian RA patients who were collected from Suez Canal University Hospital in Ismailia Governorate. The patients were newly diagnosed as having RA based on ACR 2010 Criteria for RA Classification and in the first month of MTX therapy. Both males and females were included. The patients were classified after 3 months of MTX therapy into 37 responders and 37 non responders according to EULAR Response Criteria based on ΔDAS28 and DAS281. All patients were subjected to history taking and clinical examination for DAS28 scores estimation and laboratory data including RF, Anti-CCP, ESR, CRP, CBC, ALT, AST and creatinine levels were collected from the patients’ records. The genotype and allele frequencies of RFC-1 G80A SNP (rs1051266) were performed by Polymerase Chain Reaction Restriction Fragment Length Polymorphism.
No significant differences were found in genotype and allele frequencies in addition to all genetic models between MTX responders and nonresponders.